Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Capital Expenditures (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Capital Expenditures over the past 16 years, most recently at $2.1 million for Q2 2025.

  • Quarterly results put Capital Expenditures at $2.1 million for Q2 2025, down 22.71% from a year ago — trailing twelve months through May 2025 was $13.4 million (down 27.07% YoY), and the annual figure for FY2025 was $13.4 million, down 27.07%.
  • Capital Expenditures for Q2 2025 was $2.1 million at Lifecore Biomedical, Inc. \De\, down from $5.5 million in the prior quarter.
  • Over the last five years, Capital Expenditures for LFCR hit a ceiling of $18.7 million in Q1 2022 and a floor of -$17.6 million in Q2 2022.
  • Median Capital Expenditures over the past 5 years was $3.0 million (2022), compared with a mean of $3.3 million.
  • Peak annual rise in Capital Expenditures hit 1567.08% in 2022, while the deepest fall reached 588.42% in 2022.
  • Lifecore Biomedical, Inc. \De\'s Capital Expenditures stood at -$889000.0 in 2021, then grew by 25.65% to -$661000.0 in 2022, then soared by 791.98% to $4.6 million in 2023, then tumbled by 46.66% to $2.4 million in 2024, then decreased by 14.06% to $2.1 million in 2025.
  • The last three reported values for Capital Expenditures were $2.1 million (Q2 2025), $5.5 million (Q1 2025), and $2.4 million (Q4 2024) per Business Quant data.